Related Experiment Videos
Thalidomide enhances superoxide anion release from human polymorphonuclear and mononuclear leukocytes
Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. Section C, Immunology
|December 1, 1986
Summary
Thalidomide enhances superoxide anion release from human phagocytes like polymorphonuclear leukocytes (PMNs) and monocytes when stimulated. This priming effect suggests a role in immune responses, particularly in conditions with impaired oxidative burst.
Area of Science:
- Immunology
- Pharmacology
Background:
- Thalidomide is known for its immunomodulatory effects.
- The precise mechanisms underlying thalidomide's influence on innate immune cells are not fully understood.
Purpose of the Study:
- To investigate the in vitro effects of thalidomide on human polymorphonuclear leukocytes (PMNs) and blood monocytes.
- To determine if thalidomide impacts phagocyte migration, oxygen consumption, or superoxide anion release.
Main Methods:
- Human PMNs and monocytes were incubated with varying concentrations of thalidomide.
- Cellular functions including chemotaxis, spontaneous migration, oxygen consumption, and superoxide anion release upon stimulation were assessed.
- Experiments included cells from patients with chronic granulomatous disease.
Main Results:
- Thalidomide did not affect the chemotactic or spontaneous migration of PMNs.
- PMN oxygen consumption remained unchanged after thalidomide pre-incubation.
- Superoxide anion release upon stimulation was enhanced in a dose-dependent manner in both PMNs and monocytes.
- Cells from chronic granulomatous disease patients showed no superoxide production, indicating thalidomide acts on the oxidative burst pathway.
Conclusions:
- Thalidomide primes phagocytes (PMNs and monocytes) to exhibit enhanced superoxide anion release when stimulated.
- These findings may offer insights into thalidomide's anti-inflammatory effects and its relevance in diseases with phagocyte oxidative responsiveness defects.